Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TK1 | P04183 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1259261 | 0.90 | HIF1A (0.50) | HIF1AHTTALDH1A1CYP2D6HSD17B10 | |
| SCHEMBL2111572 | 0.84 | KIF11 (0.50) | ALDH1A1CYP2D6CYP2C19CTSKTK1 | |
| SCHEMBL4771137 | 0.81 | TK1 (0.48) | CYP2D6CYP2C19CTSKTK1LMNA | |
| SCHEMBL9613450 | 0.81 | TK1 (0.45) | HTTCYP2D6CYP2C19CTSKTK1 | |
| SCHEMBL21087595 | 0.81 | TK1 (0.48) | CYP2D6CYP2C19CTSKTK1LMNA | |
| SCHEMBL9613862 | 0.80 | ABCB1 (0.41) | CTSKMEN1KMT2ATK1ABCB1 | |
| SCHEMBL15827068 | 0.79 | MAPT (0.49) | CYP2D6CYP2C19CTSKTK1LMNA | |
| SCHEMBL6569810 | 0.79 | LMNA (0.43) | ALDH1A1CYP2D6CYP2C19CTSKMEN1 | |
| SCHEMBL465454 | 0.79 | TK1 (0.46) | CYP2C19CTSKMEN1KMT2ATK1 | |
| SCHEMBL6522822 | 0.79 | TK1 (0.46) | CYP2C19CTSKMEN1KMT2ATK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3100718-A1 | IMPROVED COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | Arbutus Biopharma Corporation (CA) | 2016-12-07 | — | — | EP | disclosed |
| EP-3100718-A1 | IMPROVED COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | Arbutus Biopharma Corporation (CA) | 2016-12-07 | — | — | EP | disclosed |
| EP-2224912-B1 | IMPROVED COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORP (CA) | 2016-05-11 | — | — | EP | disclosed |
| EP-2224912-B1 | IMPROVED COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORP (CA) | 2016-05-11 | — | — | EP | disclosed |
| US-20110117125-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2011-05-19 | — | — | US | disclosed |
| US-20110117125-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2011-05-19 | — | — | US | disclosed |
| US-20110117125-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2011-05-19 | — | — | US | disclosed |
| EP-2224912-A1 | IMPROVED COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | TEKMIRA Pharmaceuticals Corporation (CA) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009086558-A1 | IMPROVED COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086558-A1 | IMPROVED COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117125-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | LDLR, SNRPE, SARNP | HIF1A 1366/4885HTT 382/4885ALDH1A1 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.